- Conditions
- Sickle Cell Disease, Sickle Cell Anemia
- Interventions
- Pociredir oral capsule(s)
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Atlanta, Georgia + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Adult Subjects
- Interventions
- Losmapimod 15 mg oral tablet, Losmapimod two 7.5 mg oral tablets, Losmapimod one 15 mg oral tablet
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Sickle Cell Disease
- Interventions
- Pociredir
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Baton Rouge, Louisiana + 5 more
- Conditions
- COVID-19
- Interventions
- Losmapimod oral tablet, Placebo oral tablet
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Irvine, California • Miami, Florida • Tampa, Florida + 2 more
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- Losmapimod, Placebo oral tablet
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 14
- States / cities
- Irvine, California • Los Angeles, California • Aurora, Colorado + 11 more
- Conditions
- Sickle Cell Disease
- Interventions
- Pociredir
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 6
- States / cities
- Miami, Florida • Orlando, Florida • Riverdale, Georgia + 3 more
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- Losmapimod oral tablet, Placebo oral tablet
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 12
- States / cities
- Irvine, California • Los Angeles, California • Gainesville, Florida + 9 more
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- Losmapimod
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 12
- States / cities
- Irvine, California • Los Angeles, California • Gainesville, Florida + 9 more
- Conditions
- Healthy Adult Subjects, Sickle Cell Disease
- Interventions
- FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Overland Park, Kansas